当前位置:
X-MOL 学术
›
Asian Pac. J. Allergy Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Asthma does not increase COVID-19 mortality and poor outcomes: A systematic review and meta-analysis.
Asian Pacific Journal of Allergy and Immunology ( IF 2.3 ) Pub Date : 2021-04-18 , DOI: 10.12932/ap-110920-0955 Arto Yuwono Soeroto 1, 2 , Aga Purwiga 2 , Emmy H Pranggono Emmy H Pranggono 1, 2 , Rully M A Roesli 2
Asian Pacific Journal of Allergy and Immunology ( IF 2.3 ) Pub Date : 2021-04-18 , DOI: 10.12932/ap-110920-0955 Arto Yuwono Soeroto 1, 2 , Aga Purwiga 2 , Emmy H Pranggono Emmy H Pranggono 1, 2 , Rully M A Roesli 2
Affiliation
The Center for Disease Control and Prevention (CDC) has mentioned Coronavirus Disease 2019 (COVID-19) patients with moderate or severe asthma as a high risk group for severe illness. While WHO mentioned only chronic respiratory diseases, not specifically asthma as a risk factor for severe illness. There has been asthma prevalence discrepancy in studies of COVID-19 across the world.
中文翻译:
哮喘不会增加 COVID-19 死亡率和不良结局:系统评价和荟萃分析。
美国疾病控制与预防中心 (CDC) 已将患有中度或重度哮喘的 2019 冠状病毒病 (COVID-19) 患者列为重症高危人群。虽然世卫组织只提到慢性呼吸道疾病,但没有具体提到哮喘是严重疾病的危险因素。世界各地的 COVID-19 研究中哮喘患病率存在差异。
更新日期:2021-04-21
中文翻译:
哮喘不会增加 COVID-19 死亡率和不良结局:系统评价和荟萃分析。
美国疾病控制与预防中心 (CDC) 已将患有中度或重度哮喘的 2019 冠状病毒病 (COVID-19) 患者列为重症高危人群。虽然世卫组织只提到慢性呼吸道疾病,但没有具体提到哮喘是严重疾病的危险因素。世界各地的 COVID-19 研究中哮喘患病率存在差异。